|
| (3S)-3-amino-4-(1H-imidazol-5-yl)-1-[4-[2-(4-methylphenyl)ethynyl]phenyl]butan-2-one |
|
Brucella |
Others |
Preclinical (in vitro) |
Abdo MR, et al. 2011. Org Biomol Chem |
|
| (3S)-3-amino-4-(1H-imidazol-5-yl)-1-[4-[4-(trifluoromethyl)phenyl]phenyl]butan-2-one |
|
Brucella |
Others |
Preclinical (in vitro) |
Abdo MR, et al. 2011. Org Biomol Chem |
|
| N-(2-fluorophenyl)-4-methyl-3-(pyridin-4-ylmethylideneamino)-1,3-thiazol-2-imine |
|
Burkholderia |
Quorum-sensing |
Preclinical (in vitro) |
Christensen QH, et al. 2013. Proc Natl Acad Sci U S A |
|
| Beta-Resorcylic acid |
|
Campylobacter |
Regulation |
Preclinical (in vitro) |
Ammar AM, et al. 2020. Animals (Basel) |
|
| 4-[(3-ethoxy-2-hydroxyphenyl)methyl]-N-(4-fluorophenyl)-5-oxo-1,3,4-thiadiazine-2-carboxamide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Zigangirova NA, et al. 2012. Acta Naturae |
|
| N'-(2-Hydroxy-3,5-dibromobenzylidene)-4-nitrobenzhydrazide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Wolf K, et al. 2006. Mol Microbiol |
|
| N-[(E)-(3-fluoro-2-hydroxyphenyl)methylideneamino]-4-nitrobenzamide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dahlgren MK, et al. 2010. Bioorg Med Chem |
|
| N'-[(E)-(5-bromo-2-hydroxyphenyl)methylidene]-2-phenylacetohydrazide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dahlgren MK, et al. 2010. Bioorg Med Chem |
|
| (E)-N'-(5-Bromo-2-hydroxybenzylidene)-3-methoxybenzohydrazide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dahlgren MK, et al. 2010. Bioorg Med Chem |
|
| N-[(E)-(5-tert-butyl-2-hydroxyphenyl)methylideneamino]-4-methylbenzamide |
|
Chlamydia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dahlgren MK, et al. 2010. Bioorg Med Chem |
|
| | | |
